Literature DB >> 29296703

Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study.

Upama Giri1, Michael G Martin2.   

Abstract

Entities:  

Year:  2017        PMID： 29296703      PMCID： PMC5728349          DOI： 10.1182/bloodadvances.2016002675

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  21 in total

1.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

2.  Non-Hodgkin's lymphoma in patients 80 years of age or older.

Authors:  O Bairey; O Benjamini; D Blickstein; A Elis; R Ruchlemer
Journal:  Ann Oncol       Date:  2006-02-28       Impact factor: 32.976

3.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

4.  Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.

Authors:  Antonino Musolino; Daniela Boggiani; Michele Panebianco; Giovanna Vasini; Stefania Salvagni; Vittorio Franciosi; Andrea Ardizzoni
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

Review 5.  Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

Authors:  John G Gribben; Nathan Fowler; Franck Morschhauser
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

Review 6.  Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions.

Authors:  Shadi Latta; Peter H Cygan; Walter Fried; Chadi Nabhan
Journal:  Oncology (Williston Park)       Date:  2013-02       Impact factor: 2.990

Review 7.  Lymphoma in older patients.

Authors:  Catherine Thieblemont; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

8.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

9.  Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA.

Authors:  A Trebouet; T Marchand; R Lemal; E Gyan; F Broussais-Guillaumot; Y Guillermin; H Monjanel; G Salles; S Le Gouill; P Godmer; C Fruchart; G Damaj; P Feugier; C Thieblemont; M Maynadié; A Monnereau; X Troussard; D Rossille; T Lamy; R Houot
Journal:  Ann Oncol       Date:  2013-08-22       Impact factor: 32.976

10.  Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

Authors:  Michael Crump; Sirpa Leppä; Luis Fayad; Je Jung Lee; Alice Di Rocco; Michinori Ogura; Hans Hagberg; Frederick Schnell; Robert Rifkin; Andreas Mackensen; Fritz Offner; Lauren Pinter-Brown; Sonali Smith; Kensei Tobinai; Su-Peng Yeh; Eric D Hsi; Tuan Nguyen; Peipei Shi; Marjo Hahka-Kemppinen; Don Thornton; Boris Lin; Brad Kahl; Norbert Schmitz; Kerry J Savage; Thomas Habermann
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544
View more
  3 in total

1.  Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?

Authors:  Narendranath Epperla; John L Vaughn; Megan Othus; Abrahao Hallack; Luciano J Costa
Journal:  Cancer Med       Date:  2020-06-18       Impact factor: 4.452

2.  Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.

Authors:  L Hounsome; T A Eyre; R Ireland; A Hodson; R Walewska; K Ardeshna; S Chaganti; P McKay; A Davies; C P Fox; N Kalakonda; P A Fields
Journal:  Br J Cancer       Date:  2021-10-05       Impact factor: 7.640

3.  Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018.

Authors:  Müjde Durmaz; Otto Visser; Eduardus F M Posthuma; Rolf E Brouwer; Djamila E Issa; Daphne de Jong; King H Lam; Nicole M A Blijlevens; Josée M Zijlstra; Martine E D Chamuleau; Pieternella J Lugtenburg; Marie José Kersten; Avinash G Dinmohamed
Journal:  Blood Cancer J       Date:  2022-03-09       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.